CPA
TXG icon

Capital Performance Advisors’s 10x Genomics TXG Stock Holding History

Capital Performance Advisors’s Portfolio TXG Stock Details TXG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-10,634
Closed -$226K – 477
2026
Q1 		$226K Buy
10,634
+367
+4% +$7.34K 0.02% 402
2025
Q4 		$167K Buy
10,267
+138
+1% +$2.08K 0.01% 427
2025
Q3 		$118K Buy
+10,129
New +$132K 0.02% 333
2024
Q4 		– Sell
-1,555
Closed -$35.1K – 2514
2024
Q3 		$35.1K Buy
+1,555
New +$32.1K 0.01% 445

Other funds holding TXG

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
QCM
Quantinno Capital Management New York $83.3B AUM 37.97% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Capital Performance Advisors's TXG Position: Q2 2026 in Review

Capital Performance Advisors sold out of 10x Genomics (TXG) in Q2 2026, closing a stake of 10,634 shares — an estimated $226K sold.

Capital Performance Advisors first reported a position in TXG in Q3 2024 and held it in 4 quarters. The position peaked at $226K in Q1 2026. 390 funds tracked by Wall St. Rank hold TXG as of Q2 2026.

  • Capital Performance Advisors reported no remaining 10x Genomics position as of Q2 2026 after selling out during the quarter.
  • Capital Performance Advisors sold 10,634 10x Genomics shares in Q2 2026, an estimated $226K.
  • Capital Performance Advisors first reported a position in 10x Genomics in Q3 2024 and held it in 4 quarters.
  • Capital Performance Advisors's 10x Genomics position peaked at $226K in Q1 2026.
  • 390 funds tracked by Wall St. Rank held 10x Genomics as of Q2 2026.

Based on Capital Performance Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.